New approaches to pharmacogenetics of drug-induced hyperprolactinemia in patients with schizophrenia
https://doi.org/10.31363/2313-7053-2019-4-1-21-23
Abstract
The pathogenesis of the development of drug-induced disorders while taking antipsychotic drugs is not well understood. The aim of the work is to study polymorphic variants of the multidrug resistance protein gene and genes encoding the metabolism and synthesis of dopamine and serotonin enzymes in antipsychotic-induced hyperprolactinemia in schizophrenia patients. As a result of a comprehensive study of 446 patients with schizophrenia and genotyping of 25 polymorphic variants of the MDR1, COMT, MAO-A, MAO-B, TPH1 and TPH2 genes, associations of polymorphisms rs1045642, rs2032582, rs4148739 (MDR1), rs6323 (MAO-А), rs1799836 (MAO-B) were revealed with the development of hyperprolactinemia. Further research is needed to develop personalized approaches to therapy.
About the Author
S. A. Ivanova
Mental Health Research Institute; Tomsk National Research Medical Center of the Russian Academy of Sciences
Russian Federation
Russian Federation
References
1. Gorobets LN Nejroehndokrinnye disfunkcii i nejrolepticheskaya terapiya. M.: Medpraktika; 2007. (In Russ.).
2. Ivanova SA, Fedorenko OYu, Smirnova LP, Semke AV. The search for biomarkers and the development of pharmacogenetic approaches to personalized treatment of patients with schizophrenia. Sibirskij vestnik psihiatrii i narkologii. 2013;1:12–16 (in Russ.).
3. Kibitov AO, Ivaschenko DV, Syichev DA. Pharmacogenetic approach to increase efficacy and safety of schizophrenia treatment with antipsychotics. Sovremennaya terapiya psihicheskih rasstroystv. 2017;1:2-13. (In Russ.).] DOI: 10.21265/ PSYPH.2017.40.4982.
4. Müller D.J., Chowdhury N.I., Zai C.C. The pharmacogenetics of antipsychotic-induced adverse events. Current Opinion in Psychiatry. 2013;26 (2): 144-150. doi:10.1097/YCO.0b013e32835dc9da
5. Ivanova S.A., Osmanova D.Z., Freidin M.B., Fedorenko O.Y., Boiko A.S., Pozhidaev I.V., Semke A.V., Bokhan N.A., Agarkov A.A., Wilffert B., Loonen A.J. Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. The World Journal of Biological Psychiatry. 2017;18(3):239-246. doi: 10.1080/15622975.2016.1224926
6. Fedorenko O.Y., Loonen A.J., Vyalova N.M., Boiko А.S., Pozhidaev I.V., Osmanova D.Z., Bokhan N.А., Ivanov M.V., Freidin M.B., Ivanova S.А. Hyperprolactinemia and CYP2D6, DRD2, HTR2C genes polymorphism in patients with schizophrenia. Physiology and Pharmacology. 2017;21 (1):25-33.
Review
For citations:
Ivanova S.A. New approaches to pharmacogenetics of drug-induced hyperprolactinemia in patients with schizophrenia. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2019;(4-1):21-23. (In Russ.) https://doi.org/10.31363/2313-7053-2019-4-1-21-23
Views:
599
Email this article 